Skip to main content

Advertisement

Table 2 Treatment-related adverse events

From: Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

  Grades 1/2 Grade 3 Grades 4/5 All grades (%) ≥Grade 3 (%)
Hematologic AEs
 Overall     94.4 33.3
 Leucopenia 14 1 0 41.7 2.8
 Neutropenia 12 7 1 55.6 22.2
 Anemia 27 2 0 80.5 5.6
 Thrombocytopenia 19 2 0 58.3 5.6
Non-hematologic AEs
 Elevated AST 11 0 0 30.5 0
 Elevated ALT 6 0 0 16.7 0
 Hyperbilirubinemia 2 0 0 5.6 0
 Fatigue 7 3 0 27.8 8.3
 Anorexia 9 2 0 27.8 5.6
 Nausea 4 0 0 11.1 0
 Vomiting 3 1 0 11.1 2.8
 Diarrhea 4 2 0 16.7 5.6
 Stomatitis 5 0 0 11.1 0
 Hand–foot syndrome 18 3 0 58.3 8.3
 Injection site reaction 3 0 0 8.3 0
 Neuropathy (sensory) 25 5 0 83.3 13.9
 Allergy 2 0 0 5.6 0
Bevacizumab-associated AEs
 Hypertension 6 4 0 27.8 11.1
 Proteinuria 11 2 0 36.1 5.6
 Thrombosis 0 1 0 2.8 2.8
 Bleeding 1 1 1 8.3 5.6
  1. AE adverse effect